Wells Fargo & Company MN Grows Stock Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC)

Wells Fargo & Company MN raised its stake in Revance Therapeutics, Inc. (NASDAQ:RVNC) by 27.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 49,373 shares of the biopharmaceutical company’s stock after buying an additional 10,675 shares during the quarter. Wells Fargo & Company MN’s holdings in Revance Therapeutics were worth $150,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. RPO LLC acquired a new position in Revance Therapeutics in the 4th quarter valued at about $55,000. KLP Kapitalforvaltning AS purchased a new position in Revance Therapeutics during the fourth quarter worth about $74,000. Deltec Asset Management LLC acquired a new position in shares of Revance Therapeutics in the 4th quarter worth approximately $304,000. Inspire Investing LLC raised its position in Revance Therapeutics by 69.0% in the fourth quarter. Inspire Investing LLC now owns 131,892 shares of the biopharmaceutical company’s stock valued at $401,000 after purchasing an additional 53,837 shares during the period. Finally, Rhumbline Advisers boosted its position in shares of Revance Therapeutics by 5.1% during the fourth quarter. Rhumbline Advisers now owns 142,603 shares of the biopharmaceutical company’s stock worth $434,000 after buying an additional 6,885 shares during the period. Institutional investors and hedge funds own 97.70% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on RVNC shares. Needham & Company LLC reissued a “hold” rating on shares of Revance Therapeutics in a research report on Friday, January 17th. StockNews.com started coverage on shares of Revance Therapeutics in a research note on Monday, May 5th. They issued a “hold” rating for the company. Nine research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, Revance Therapeutics has an average rating of “Hold” and an average target price of $8.39.

Revance Therapeutics Price Performance

Shares of NASDAQ RVNC opened at $3.65 on Friday. The stock has a market cap of $381.02 million, a PE ratio of -1.89 and a beta of 0.90. Revance Therapeutics, Inc. has a 52-week low of $2.30 and a 52-week high of $6.65. The business has a 50-day moving average price of $3.65 and a 200 day moving average price of $3.75.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.